Generics of Complex Drugs Must Pass Korea FDA's Bioequivalence Test; Another Positive Development for MNCs
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Korea's Food and Drug Administration will soon require medicines made by Korean generic drug makers to pass the agency's bioequivalence test when producing copies of branded originals with more than two active ingredients, also known as complex drugs
You may also be interested in...
GSK Expands In Korea With Purchase Of Equity Stake In Dong-A Pharma
GlaxoSmithKline is paying 142.9 billion South Korean won ($128.7 million) to acquire a 9.9 percent stake in Dong-A Pharmaceutical, South Korea's leading Rx and OTC company. The strategic alliance should help GSK gain share in the rapidly growing Korean pharmaceutical market
GSK Expands In Korea With Purchase Of Equity Stake In Dong-A Pharma
GlaxoSmithKline is paying 142.9 billion South Korean won ($128.7 million) to acquire a 9.9 percent stake in Dong-A Pharmaceutical, South Korea's leading Rx and OTC company. The strategic alliance should help GSK gain share in the rapidly growing Korean pharmaceutical market
GSK Expands In Korea With Purchase Of Equity Stake In Dong-A Pharma
GlaxoSmithKline is paying 142.9 billion South Korean won ($128.7 million) to acquire a 9.9 percent stake in Dong-A Pharmaceutical, South Korea's leading Rx and OTC company. The strategic alliance should help GSK gain share in the rapidly growing Korean pharmaceutical market